clinical trial · NCT07030699
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
LymphomaEpcoritamabLenalidomideTafasitamab
brief summary
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.
started
Aug 13, 2025
primary completion
Mar 31, 2026
completion
Mar 31, 2026
last updated
Apr 7, 2026
official title
Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol